Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanreotide - Ipsen

Drug Profile

Lanreotide - Ipsen

Alternative Names: Angiopeptin; BIM 23014; BIM 23014C; BM 23014; Dermopeptin; Ipstyl; ITM-014; ITM-014T; Lanreotide acetate; Lanreotide Autogel; Lanreotide PRF; Somatulina; Somatuline; Somatuline Autogel; Somatuline Depot; Somatuline LA; Somatuline LP

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tulane University
  • Developer Ipsen; Ipsen Biopharmaceuticals; Radboud University Nijmegen Medical Centre; Teijin Pharma
  • Class Antineoplastics; Cardiovascular therapies; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Phase III Pituitary cancer
  • Phase II Pancreatic cancer
  • Discontinued Atherosclerosis; Breast cancer; Coronary artery restenosis; Diabetic retinopathy; Gastrointestinal cancer; Graves ophthalmopathy; Intestinal obstruction; Leiomyoma; Lung cancer; Polycystic kidney disease; Polycystic liver disease; Portal hypertension; Prostate cancer; Rheumatic disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Feb 2018 Registered for Malignant carcinoid syndrome in Canada (SC)
  • 16 Jan 2018 Ipsen completes a phase-II clinical trials in Intestinal obstruction (Combination therapy) in Italy (SC) (NCT02365584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top